#162348

Anti-CD4 past the UGA codon

Cat. #162348

Anti-CD4 past the UGA codon

Cat. #: 162348

Sub-type: Primary antibody

Unit size: 100 ug

Application: ELISA

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Brady Neal Ware

Institute: University of Georgia Research Foundation, Inc.

Primary Citation: Ware, 2003, Doctoral Thesis, University of Georgia. "Gene regulation and overlooked coding regions : the case for translation past the 3'-UGA codon in CD4"

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CD4 past the UGA codon
  • Tool sub type: Primary antibody
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA
  • Description: Antibody developed against the cytoplasmic tail of CD4 just prior to the UGA codon, used as a positive control
  • Immunogen: Peptide
  • Isotype: IgM

Target Details

  • Target background: The last 20 amino acids of the accepted CD4 cytoplasmic tail. The predicted molecular weight of the peptide for the known region of cytoplasmic tail is 2334.9 Daltons. Peptide has 15 hydrophilic resides

Applications

  • Application: ELISA

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Ware, 2003, Doctoral Thesis, University of Georgia. "Gene regulation and overlooked coding regions : the case for translation past the 3'-UGA codon in CD4"

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.